{"nctId":"NCT00365456","briefTitle":"Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)","startDateStruct":{"date":"2006-07"},"conditions":["Osteoporosis"],"count":407,"armGroups":[{"label":"PTH (1-84)","type":"EXPERIMENTAL","interventionNames":["Drug: Parathyroid Hormone (PTH)"]},{"label":"Risedronate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risedronate"]}],"interventions":[{"name":"Parathyroid Hormone (PTH)","otherNames":[]},{"name":"Risedronate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nWomen above the age of 50 years with the diagnosis of postmenopausal primary osteoporosis may be enrolled in the trial if the following inclusion/exclusion criteria apply.\n\nAll inclusion criteria must be answered \"yes\" for a subject to be enrolled in the trial.\n\n1. Has the subject given informed consent according to local requirements before any trial related activities? (A trial related activity is any procedure that would not have been performed during the routine management of the subject).\n2. Is the subject above 50 years old?\n3. Is the subject postmenopausal (more than 5 years) - in the judgement of the investigator?\n4. Does the subject have primary osteoporosis with a lumbar spine T score \\< -3.0 SD (at lumbar spine L1-L4, with a minimum of two evaluable vertebrae)?\n5. Does the subject have a life expectancy of \\>3 years?\n6. Is the subject able to self-inject PTH (1-84), (or to have PTH (1-84) injection by a helper)?","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III.","description":"BMD was measured by Dual X-ray Absorptiometry (DXA).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.002","spread":"1.0037"},{"groupId":"OG001","value":"0.990","spread":"1.0034"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":405},"commonTop":["Hypercalciuria","Hypercalcaemia","Nausea","Back pain","Urinary tract infection"]}}}